Affordable Access

[Bacteriological, pharmacokinetic and clinical studies of a rokitamycin syrup in pediatrics].

Authors
  • Sato, H
  • Narita, A
  • Matsumoto, K
  • Nakazawa, S
  • Suzuki, H
  • Nakanishi, Y
  • Nakazawa, S
  • Chikaoka, H
  • Koido, R
  • Kamigaki, M
Type
Published Article
Journal
The Japanese journal of antibiotics
Publication Date
Jun 01, 1988
Volume
41
Issue
6
Pages
696–711
Identifiers
PMID: 3221434
Source
Medline
License
Unknown

Abstract

Rokitamycin (RKM) dry syrup was administered to a group of pediatric patients. The results obtained are summarized as follows. 1. Of the recent isolates of Streptococcus pyogenes, fewer strains were highly resistant to RKM than to josamycin (JM), midecamycin (MDM), erythromycin and lincomycin. Also, macrolides (MLs)-resistant strains proved to be susceptible to RKM. 2. Recent isolates of Staphylococcus aureus, Streptococcus agalactiae, group G Streptococci, S. pyogenes, Streptococcus pneumoniae and Haemophilus influenzae were more susceptible to RKM than to midecamycin acetate and JM. Oral administrations of 10-15 mg/kg of the drug were followed by its peak concentrations of 0.07-0.77 micrograms/ml in the blood at 30 minutes in many patients, and by an undetectable level at 6 hours also in many of them. T1/2 values were 1.2-2.6 hours, and first 6-hour urinary excretion rates were 1.26-1.74%. 3. Fifty-two patients with acute upper and lower respiratory tract infections, Campylobacter enteritis, etc. were treated with RKM at about 20-40 mg/kg daily for 4-14 days, with an overall efficacy rate of 88.5%. 4. An eradication rate of 81.4% was achieved for 43 strains of 7 species isolated from the patients. 5. No abnormal laboratory test values were observed after treatment with drug 4 approximately 14 days. A side effect, stomach discomfort, was observed in 1 patient.

Report this publication

Statistics

Seen <100 times